XTX Topco Ltd Buys 44,979 Shares of Nuvation Bio Inc. (NYSE:NUVB)

XTX Topco Ltd boosted its stake in shares of Nuvation Bio Inc. (NYSE:NUVB) by 424.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,564 shares of the company’s stock after buying an additional 44,979 shares during the quarter. XTX Topco Ltd’s holdings in Nuvation Bio were worth $98,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NUVB. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Nuvation Bio in the 4th quarter valued at about $27,000. Forum Financial Management LP bought a new stake in shares of Nuvation Bio in the 4th quarter valued at about $29,000. Cerity Partners LLC bought a new stake in shares of Nuvation Bio in the 4th quarter valued at about $31,000. Firethorn Wealth Partners LLC bought a new stake in shares of Nuvation Bio in the 1st quarter valued at about $35,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Nuvation Bio by 15,183.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock valued at $42,000 after purchasing an additional 15,791 shares in the last quarter. Institutional investors own 61.67% of the company’s stock.

Nuvation Bio Stock Up 5.6%

NYSE:NUVB opened at $2.76 on Friday. The company has a market cap of $937.42 million, a PE ratio of -4.37 and a beta of 1.35. Nuvation Bio Inc. has a twelve month low of $1.54 and a twelve month high of $3.45. The company has a current ratio of 9.39, a quick ratio of 9.38 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $2.20 and its two-hundred day moving average is $2.14.

Nuvation Bio (NYSE:NUVB) last released its earnings results on Thursday, August 7th. The company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). Nuvation Bio had a negative net margin of 1,413.43% and a negative return on equity of 46.14%. The company had revenue of $4.83 million for the quarter, compared to the consensus estimate of $0.42 million. Analysts anticipate that Nuvation Bio Inc. will post -0.36 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on NUVB. Wall Street Zen lowered shares of Nuvation Bio from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Wedbush restated an “outperform” rating and issued a $5.00 price target on shares of Nuvation Bio in a report on Wednesday, June 11th. JMP Securities reaffirmed a “market outperform” rating and issued a $6.00 price objective on shares of Nuvation Bio in a research report on Wednesday, June 25th. Citigroup began coverage on shares of Nuvation Bio in a research report on Wednesday, April 23rd. They issued an “outperform” rating on the stock. Finally, Royal Bank Of Canada lifted their price objective on shares of Nuvation Bio from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.